Gilead Sciences, Inc. (NASDAQ:GILD) Q3 2024 Earnings Call Transcript November 6, 2024 Gilead Sciences, Inc. beats earnings expectations. Reported EPS is $2.02, expectations were $1.53. Operator: Good ...

Third Quarter 2024 Results Key Financial Results Revenue: US$7.55b (up 7.0% from ...

Headquartered in Foster City, California, Gilead Sciences, Inc. (GILD) is a prominent biopharmaceutical company with a market cap of $114.2 billion. Gilead specializes in developing and delivering ...

Daina Graybosch’s rating is based on Gilead Sciences’ strong financial performance and promising pipeline developments. The company reported impressive third-quarter results, with both revenue and ...

Of the top 20, Novo and Lilly were among only six companies that witnessed declines in their market value in the third ...

The China International Import Expo has consistently demonstrated China's strong commitment to promoting high-level openness ...

An ex-Gilead worker who says he was illegally fired for refusing to steal confidential material isn’t protected by a ...

LB Denzel Perryman, OL Trey Pipkins III, former Chargers outside linebacker Larry English and many volunteers gathered at U.S ...

A Pennsylvania federal district court denied summary judgment to Gilead Sciences, Inc. on the wrongful discharge claim under state law of an employed at-will therapeutic specialist who sold its ...

Born in Lincolnville, South Carolina, Dr. Pernessa Seele has dedicated over 37 years to bridging the gap between faith and ...

Gilead (GILD) announced the upcoming presentation of HIV research findings at the International Congress on Drug Therapy in HIV Infection, ...

Gilead stock surges after Q3 earnings beat estimates and raised FY 2024 guidance, with strong HIV drug sales and analyst ...